Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug aims to slow kidney damage in rare disease

NCT ID NCT07157787

Disease control Sponsor: Alexion Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests an experimental drug called ALXN1920 in 30 adults with primary membranous nephropathy, a rare kidney disease that can lead to kidney failure. Participants are at high risk for their disease getting worse. The study compares the drug to a placebo to see if it reduces protein in the urine, a sign of kidney damage, over 26 weeks. All participants continue their standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2025

Expected to finish

Jul 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participants who have a documented diagnosis of PMN, established by positive antiPLA2R antibody level (\> 20 RU/mL) at Screening, which must be confirmed by a central laboratory * Participants are willing to receive the background Standard of Care (SoC) * Participants at high risk for disease progression, defined as: 1. Receiving ACE inhibitor or ARB for a minimum of 8 weeks prior to Screening, with the dose titrated to the maximally tolerated level. Participants with less than 8 weeks on ACE inhibitor or ARB before Screening or who have not yet reached maximally tolerated dose will enter the Run-in Period. 2. Participants who are on ACE inhibitor or ARB for a minimum of 8 weeks with Systolic Blood Pressure \< 140 mmHg in ≥ 75% of the readings within last 8 weeks. 3. Having two proteinuria measurements with each \> 3.5 g/day, the second measurement showing ≤50% decrease from the first measurement. * eGFR60 mL/min/1.73 m2 during Screening calculated by CKD-EPI 2021 creatinine formula * All participants must receive prophylactic treatment with appropriate antibiotics while receiving Rituximab (RTX), and be willing to be vaccinated against Neisseria meningitidis Exclusion Criteria: * Documented rapid deterioration of kidney function * History of life-threatening Nephrotic Syndrome within 1 year before Screening * Diagnosis of anti- phospholipase A2 receptor (PLA2R) negative membranous nephropathy (MN) or anti-PLA2R positive MN but Screening serum anti-PLA2R \< 20 RU/mL or kidney disease other than PMN * History of kidney transplant or planned kidney transplant or dialysis during the Treatment Period * History of other solid organ (heart, lung, small bowel, pancreas, or liver) or bone marrow transplant; or planned transplant during the Treatment Period * History or presence of any clinically relevant co-morbidities * History of intolerance or hypersensitivity to ACEi or ARB * Initiation or dose adjustment of SGLT2i within 12 weeks prior to randomization or planned adjustment of GSLT2i dose throughout the treatment period. * Use of traditional Chinese medicines or Chinese proprietary medicines with systemic immunosuppressive properties within 6 months prior to screening. * Use of MRA, or ERA within 12 weeks prior to randomization and throughout the study period Note: Additional inclusion/exclusion criteria may apply, per protocol.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Primary membranous nephropathy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

idiopathic membranous glomerulonephritis membranous glomerulonephritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Primary membranous nephropathy

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    36 sites in 10 countries. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Research Site

    RECRUITING

    Loma Linda, California, 92354, United States

  • Research Site

    RECRUITING

    San Diego, California, 92123, United States

  • Research Site

    RECRUITING

    Minneapolis, Minnesota, 55435, United States

  • Research Site

    RECRUITING

    Rochester, Minnesota, 55905, United States

  • Research Site

    RECRUITING

    Houston, Texas, 77030, United States

  • Research Site

    RECRUITING

    Buenos Aires, 1425, Argentina

  • Research Site

    RECRUITING

    CABA, C1425HFA, Argentina

  • Research Site

    RECRUITING

    Ciudad de Buenos Aires, 1280, Argentina

  • Research Site

    NOT_YET_RECRUITING

    La Plata, B1902COS, Argentina

  • Research Site

    RECRUITING

    Rosario, 2000, Argentina

  • Research Site

    WITHDRAWN

    Santa Fe, S3000EOZ, Argentina

  • Research Site

    WITHDRAWN

    Santa Fe, S3000, Argentina

  • Research Site

    ACTIVE_NOT_RECRUITING

    Gosford, 2250, Australia

  • Research Site

    RECRUITING

    Parkville, 3050, Australia

  • Research Site

    RECRUITING

    Southport, 4222, Australia

  • Research Site

    RECRUITING

    Recife, 50670-901, Brazil

  • Research Site

    RECRUITING

    Salvador, 40301-155, Brazil

  • Research Site

    RECRUITING

    São Paulo, 04038-002, Brazil

  • Research Site

    RECRUITING

    São Paulo, 05403-000, Brazil

  • Research Site

    RECRUITING

    Baotou, 014010, China

  • Research Site

    RECRUITING

    Beijing, 100034, China

  • Research Site

    RECRUITING

    Guangzhou, 510080, China

  • Research Site

    RECRUITING

    Shenzhen, 518036, China

  • Research Site

    WITHDRAWN

    Créteil, 94010, France

  • Research Site

    RECRUITING

    Nice, 06000, France

  • Research Site

    RECRUITING

    Toulouse, 31059, France

  • Research Site

    RECRUITING

    Milan, 20122, Italy

  • Research Site

    RECRUITING

    Ranica, 24020, Italy

  • Research Site

    RECRUITING

    Torrette, 60126, Italy

  • Research Site

    RECRUITING

    Barcelona, 08025, Spain

  • Research Site

    RECRUITING

    Madrid, 28007, Spain

  • Research Site

    RECRUITING

    Seville, 41013, Spain

  • Research Site

    RECRUITING

    Toledo, 45007, Spain

  • Research Site

    RECRUITING

    Kaohsiung City, 81362, Taiwan

  • Research Site

    RECRUITING

    Taichung, 40705, Taiwan

  • Research Site

    RECRUITING

    Taoyuan, 333, Taiwan

  • Research Site

    RECRUITING

    Cambridge, CB2 0QQ, United Kingdom

  • Research Site

    RECRUITING

    Leicester, LE5 4PW, United Kingdom

  • Research Site

    RECRUITING

    London, SE5 9RJ, United Kingdom

  • Research Site

    RECRUITING

    Salford, M6 8HD, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.